MX2018008226A - Composicion inmunogenica. - Google Patents

Composicion inmunogenica.

Info

Publication number
MX2018008226A
MX2018008226A MX2018008226A MX2018008226A MX2018008226A MX 2018008226 A MX2018008226 A MX 2018008226A MX 2018008226 A MX2018008226 A MX 2018008226A MX 2018008226 A MX2018008226 A MX 2018008226A MX 2018008226 A MX2018008226 A MX 2018008226A
Authority
MX
Mexico
Prior art keywords
kill
prime
gene encoding
killing
immunogenic composition
Prior art date
Application number
MX2018008226A
Other languages
English (en)
Inventor
Marie- Paule Simone Jeanne FERON Christiane
Giannini Sandra
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2018008226A publication Critical patent/MX2018008226A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01087—Capsular-polysaccharide endo-1,3-alpha-galactosidase (3.2.1.87)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención describe un bacteriófago recombinante que comprende un polinucleótido de genoma de fago que incluye un gen que codifica una o varias proteínas antigénicas heterólogas y un gen eliminador que codifica una proteína que es capaz de matar a una bacteria hospedera. Tal bacteriófago recombinante está diseñado para activar una respuesta inmunitaria en un sujeto y para matar a la bacteria que infecta de manera tal que el bacteriófago de "cebar y matar" proporciona dos líneas de protección contra las enfermedades infecciosas.
MX2018008226A 2016-01-03 2017-01-03 Composicion inmunogenica. MX2018008226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1600075.4A GB201600075D0 (en) 2016-01-03 2016-01-03 Immunogenci composition
PCT/EP2017/050095 WO2017114979A1 (en) 2016-01-03 2017-01-03 Immunogenic composition

Publications (1)

Publication Number Publication Date
MX2018008226A true MX2018008226A (es) 2018-09-07

Family

ID=55406664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008226A MX2018008226A (es) 2016-01-03 2017-01-03 Composicion inmunogenica.

Country Status (9)

Country Link
US (2) US11998579B2 (es)
EP (1) EP3397277B1 (es)
JP (2) JP6876056B2 (es)
CN (1) CN108472391A (es)
BR (1) BR112018013503A2 (es)
CA (1) CA3009973A1 (es)
GB (1) GB201600075D0 (es)
MX (1) MX2018008226A (es)
WO (1) WO2017114979A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703006A (zh) * 2018-06-19 2021-04-23 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
US11572595B2 (en) * 2018-12-31 2023-02-07 Roche Molecular Systems, Inc. Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
US11473093B2 (en) * 2020-11-04 2022-10-18 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
CN114540389B (zh) * 2020-11-26 2024-05-14 深圳华大生命科学研究院 一种制备基因工程病毒的方法及其应用
GB202205833D0 (en) * 2022-04-21 2022-06-08 Glaxosmithkline Biologicals Sa Bacteriophage

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107319D0 (en) * 2001-03-23 2001-05-16 Moredun Res Inst Bacteriophage-mediated immunisation
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2461647C (en) * 2001-09-27 2012-01-24 Gangagen, Inc. Lysin-deficient bacteriophages having reduced immunogenicity
MXPA04002866A (es) * 2001-09-27 2005-06-06 Gangagen Inc Composiciones bacterianas inmunogeneticas de celula completa incapacitadas.
EP1487273B1 (en) * 2002-02-13 2009-01-21 Immunology Laboratories, Inc. Compositions and methods for treatment of microbial infections
WO2003076583A2 (en) 2002-03-06 2003-09-18 Musc Foundation For Research Development Genetically engineered phage and the use of genetically engineered phage to deliver nucleic acid to bacteria
GB0314469D0 (en) * 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
CN101068567A (zh) * 2004-09-17 2007-11-07 科·汉森有限公司 嵌合噬菌体衍生的颗粒，它们的制造方法和用途
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
TR201905633T4 (tr) * 2007-03-02 2019-05-21 Dupont Nutrition Biosci Aps İyileştirilmiş faj direnci olan kültürler.
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
WO2010141135A2 (en) * 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
US20120301433A1 (en) * 2009-07-29 2012-11-29 Whitehead Institute For Biomedical Research Bacteriophages expressing amyloid peptides and uses thereof
WO2014085297A1 (en) 2012-11-27 2014-06-05 Colorado State University Research Foundation Multifunctional bacteriophage for delivery of therapeutic agents and imaging reagents
GB201308742D0 (en) 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
ES2902386T1 (es) * 2013-07-01 2022-03-28 Massachusetts Inst Technology Funcionalización de bacterias endógenas
US9483624B2 (en) 2013-08-07 2016-11-01 Google Technology Holdings LLC Method and apparatus for configuring privacy settings for publishing electronic images
WO2015116531A1 (en) 2014-01-29 2015-08-06 Synphagen Llc. Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses

Also Published As

Publication number Publication date
CN108472391A (zh) 2018-08-31
US20240299474A1 (en) 2024-09-12
JP6876056B2 (ja) 2021-05-26
BR112018013503A2 (pt) 2018-12-04
GB201600075D0 (en) 2016-02-17
US20190083552A1 (en) 2019-03-21
US11998579B2 (en) 2024-06-04
EP3397277A1 (en) 2018-11-07
JP2021112202A (ja) 2021-08-05
EP3397277B1 (en) 2024-10-16
JP2019500049A (ja) 2019-01-10
CA3009973A1 (en) 2017-07-06
WO2017114979A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
MX2018008226A (es) Composicion inmunogenica.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
EP4104854A3 (en) Multivalent vaccines for rabies virus and coronaviruses
TW201612316A (en) Porcine pseudorabies virus gene deletion strain, vaccine composition, and preparation method and application of vaccine composition
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MA40765A (fr) Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
MX2016010954A (es) Construcciones de proteina superficial ubicua a2 y usos de las mismas.
MX2019012070A (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antigenos patogenicos aviares heterologos.
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
PH12020500569A1 (en) Influenza virus vaccines and uses thereof
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
MX2022006602A (es) Vacunas de herpesvirus de pavo recombinante y uso de las mismas.
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
MX2020006225A (es) Constructos antigenicos del virus de epstein-barr.
PH12017500419A1 (en) Recoded arbovirus and vaccines
MY187896A (en) Dengue virus vaccine compositions and methods of use thereof
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
PH12018502460A1 (en) Arthrogenic alphavirus vaccine
PH12020551944A1 (en) Reverse peptide vaccine
WO2021019235A3 (en) Hantavirus antigenic composition
EA202090236A1 (ru) Иммуногенные композиции senecavirus a и способы с ними
WO2018056528A3 (ko) 인플루엔자 b 백신